

Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction

Powell Jose,* Hicham Skali,* Nagesh Anavekar,[†] Charles Tomson,[‡] Harlan M. Krumholz,[§] Jean L. Rouleau,^{||} Lemuel Moye,* Marc A. Pfeffer,* and Scott D. Solomon;* for the SAVE Investigators

*Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts;

[†]University of Melbourne, Melbourne, Australia; [‡]North Bristol NHS Trust, Bristol, United Kingdom; [§]Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut; and ^{||}University of Montreal, Quebec, Canada

Baseline renal function is a potent independent risk factor for adverse events after acute myocardial infarction (MI). Worsening renal function (WRF) has been shown to influence outcomes in the heart failure population, but its impact on cardiovascular risk in the post-MI period has not been well defined. For assessment of the prognostic importance of WRF, 2231 patients who had left ventricular dysfunction and were enrolled in the Survival and Ventricular Enlargement (SAVE) trial were studied. Patients were randomly assigned between 3 and 16 d (average 11 d) after acute MI to receive captopril or placebo; those with a serum creatinine of >2.5 mg/dl were excluded from SAVE. WRF was defined as an increase in creatinine of >0.3 mg/dl measured from baseline to 2 wk after randomization. The predictive value of WRF on cardiovascular morbidity and mortality was examined during 42 mo of follow-up. Paired serum creatinine measurements at baseline and 2 wk were available in 1854 patients. WRF occurred in 223 (12.0%) patients and was a stronger predictor of death (hazard ratio [HR] 1.46; 95% confidence interval [CI] 1.05 to 2.02) than baseline creatinine (HR 1.31; 95% CI 1.01 to 1.70). WRF also showed an increased risk for cardiovascular death (HR 1.62; 95% CI 1.14 to 2.30) and the composite end point (HR 1.32; 95% CI 1.03 to 1.70). When stratified by treatment, 104 (5.7%) and 116 (6.4%) patients with WRF in the placebo and captopril groups had no significant association between treatment group and WRF ($P = 0.38$). The risk for death associated with WRF was HR 1.63 (95% CI 1.05 to 2.52) in the placebo group compared with HR 1.33 (95% CI 0.81 to 2.21) in the captopril group ($P = 0.49$ for interaction). WRF as early as 2 wk after MI was not uncommon (12.0%) and was associated with increased mortality in patients without renal dysfunction at baseline. Patients who received captopril did not demonstrate more WRF than patients who received placebo. Monitoring serum creatinine in patients during the first few weeks after MI may help to identify those who are at highest risk and guide effective long-term therapeutic choices.

J Am Soc Nephrol 17: 2886–2891, 2006. doi: 10.1681/ASN.2006010063

Renal dysfunction is a strong independent predictor of cardiovascular outcomes and mortality in the general population (1) after myocardial infarction (MI) (2–6) and heart failure (7,8). Small increases in creatinine over a specified period, defined as worsening renal function (WRF), have been assessed in heart failure patients as an independent prognostic marker (9,10). In patients who are hospitalized for acute heart failure, WRF not only has been shown to confer additional cardiovascular risk but also has been shown to be a stronger predictor of death in patients with heart failure than the initial level of creatinine (11). Nevertheless, the prognostic value of WRF in patients after acute MI is not well defined. Furthermore, whether treatment with angiotensin-converting enzyme (ACE) inhibition in these patients is associated with

WRF is unknown. We analyzed patients who were enrolled in the Survival and Ventricular Enlargement (SAVE) Trial and in whom serum creatinine was measured at baseline and at 2 wk. Our objectives were to determine the risk for all-cause and cardiovascular mortality and morbidity associated with WRF and to determine whether ACE inhibitor therapy influences this relationship.

Materials and Methods

Patients

SAVE was a randomized, double-blind, placebo-controlled trial that examined the use of the ACE inhibitor captopril in 2231 consenting patients with acute MI and left ventricular dysfunction (left ventricular ejection fraction $\leq 40\%$) (12). Patients did not have overt clinical heart failure at the time of randomization. A serum creatinine of >2.5 mg/dl was part of the exclusion criteria for SAVE. All patients received a captopril test dose of 6.25 mg; patients who developed hypotensive symptoms or ischemia after initiation of study drug ($n = 23$) were excluded from the trial. Patients were randomly assigned to receive captopril or placebo between 3 and 16 d after MI. The titration scheme involved an initial dose of 12.5 mg, which was advanced as tolerated up

Received January 21, 2006. Accepted July 6, 2006.

Published online ahead of print. Publication date available at www.jasn.org.

Address correspondence to: Dr. Scott D. Solomon, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Phone: 617-732-7182; Fax: 617-277-4981; E-mail: ssolomon@rics.bwh.harvard.edu

to 25 mg three times daily before discharge. During an outpatient visit approximately 2 wk later, at the discretion of site investigators, the dosage was to be doubled.

Serum creatinine was measured at baseline as well as during this visit after 2 wk. WRF was defined as an increase in creatinine of >0.3 mg/dl from baseline, which was the threshold value on the basis of receiver operator curve analyses from heart failure studies that demonstrated this increase to represent a clinically significant change in creatinine and was less likely to be due to laboratory assay variability (13).

From an initial 2231 patients, 356 patients were missing serum creatinine measurements at either baseline ($n = 31$) or 2 wk ($n = 325$), and 21 patients had a cardiovascular event occur before 2 wk, leaving for analysis 1854 randomly assigned and consenting SAVE patients who had baseline and 2-wk serum creatinine measurements and who at the first outpatient visit had no cardiovascular events. When the risk for WRF was stratified by treatment, 41 additional patients were not taking captopril because of dropout or adverse drug reactions such as hypotension and dizziness but not WRF, leaving 1813 patients who had paired samples and no cardiovascular events and were taking their assigned study medication after 2 wk. Death, cardiovascular death, and a composite outcome of death, stroke, recurrent MI, and hospitalization for congestive heart failure (CHF) were considered primary end points and were assessed during a follow-up period of 36.8 mo (95% confidence interval [CI] 36.2 to 37.5 mo) that commenced at the 2-week outpatient visit.

Statistical Analyses

t test and χ^2 tests were used to compare continuous and categorical variables between the groups. Cox proportional hazards models were used to derive univariate and multivariate estimates of risk for outcomes starting from the 2-wk visit after randomization, when the second creatinine was measured. We performed multivariable analyses using logistic and Cox regression to assess for independent predictors of WRF and the prognostic value of WRF after adjusting for known

cardiovascular risk factors, including age; gender; baseline creatinine (categorized as <1.0 , 1.0 to <2.0 , and ≥ 2.0 mg/dl); left ventricular ejection fraction; previous MI; use of diuretics 24 h before MI; and a history of dyslipidemia, hypertension, diabetes, or CHF. We also examined risk according to treatment assignment to determine whether captopril modifies the relationship between WRF and cardiovascular risk. Statistical analyses were performed with STATA software, version 8.2 (Stata Corp., College Station, TX).

Results

Patients who were excluded from this analysis because they were missing serum creatinine measurements ($n = 356$), had cardiovascular events ($n = 21$), or were not taking medication at 2 wk ($n = 41$) were older, were more likely to be female, had more hypertension, and were more frequent users of diuretics compared with those who were included in the analysis. Although there was a higher cardiovascular event rate in excluded patients, there was no significant difference in baseline creatinine, change in creatinine, or treatment assignment compared with the study cohort.

Of the 1854 patients who composed the study cohort, the change in creatinine from baseline to 2 wk was normally distributed, ranging from -1.2 to 2.8 mg/dl with a mean change in creatinine by treatment assignment of 0.05 ± 0.3 in both the placebo and captopril groups ($P = 0.9$). A total of 223 (12.0%) patient had WRF with no significant difference in time from onset of MI to enrollment into SAVE between patients with and without WRF (average 11 d after MI). Patients with WRF were older; were more likely to be female; and had a higher prevalence of diabetes, smoking, and use of diuretics but had fewer previous MI (Table 1). In the multivariate logistic regression model, only age (odds ratio [OR] 1.03; 95% CI 1.01 to 1.04)

Table 1. Baseline characteristics according to WRF^a

Characteristics	$\Delta\text{Cr} \leq 0.3$ ($n = 1631$), 88.0%	$\Delta\text{Cr} > 0.3$ ($n = 223$), 12.0%	<i>P</i>
Age (yr)	58.8 \pm 10.6	60.7 \pm 10.8	0.01
Creatinine (mg/dl)	1.20 \pm 0.32	1.09 \pm 0.35	<0.001
LVEF (%)	31.3 \pm 6.6	30.7 \pm 6.4	0.20
Systolic BP	112 \pm 15	114 \pm 16	0.06
Diastolic BP	70 \pm 10	70 \pm 10	0.99
Female gender	257 (15.7)	53 (23.8)	0.003
GFR < 60 ml/min per 1.73 m ²	549 (33.7)	61 (27.3)	0.06
Hypertension	677 (41.5)	103 (46.2)	0.18
Dyslipidemia	363 (24.0)	47 (23.2)	0.79
Diabetes	333 (20.4)	62 (27.8)	0.012
Previous MI	584 (37.6)	63 (29.4)	0.020
History of CHF	99 (6.1)	9 (4.0)	0.22
Smoking	328 (20.1)	60 (26.9)	0.019
Medications ^b			
diuretics	538 (34.5)	89 (41.9)	0.034
captopril therapy	819 (50.2)	119 (53.4)	0.38 ^c

^aData are mean \pm SD or n (%). t test for continuous variables, χ^2 for categorical. CHF, congestive heart failure; Cr, creatinine; LVEF, left ventricular ejection fraction; MI, myocardial infarction; WRF, worsening renal function.

^bSustained drug treatment within 24 h before randomization.

^cBy design.

Table 2. Events and risk in patients according to presence of WRF and treatment^a

Events	Δ Cr \leq 0.3 (n = 1631)	Δ Cr > 0.3 (n = 223)	Unadjusted HR (95% CI)	Adjusted HR (95% CI) ^b	Adjusted HR by Treatment ^c (95% CI; n = 1813)	
					Placebo (n = 916)	Captopril (n = 897) ^d
Death	316 (19.4%)	58 (26.0%)	1.46 (1.10 to 1.93)	1.46 (1.05 to 2.02)	1.63 (1.05 to 2.52)	1.33 (0.81 to 2.21)
Cardiovascular death	260 (15.9%)	51 (22.9%)	1.55 (1.15 to 2.09)	1.62 (1.14 to 2.30)	1.74 (1.07 to 2.81)	1.56 (0.92 to 2.63)
MI	205 (12.6%)	32 (14.3%)	1.23 (0.84 to 1.78)	1.04 (0.66 to 1.66)	1.38 (0.78 to 2.47)	0.70 (0.31 to 1.54)
CHF	236 (14.5%)	39 (17.5%)	1.48 (1.05 to 2.07)	1.35 (0.91 to 2.01)	1.53 (1.08 to 2.16)	1.20 (0.82 to 1.75)
Composite end point ^e	564 (34.6%)	94 (42.1%)	1.41 (1.14 to 1.76)	1.32 (1.03 to 1.70)	1.53 (1.08 to 2.16)	1.20 (0.82 to 1.75)

^aCI, confidence interval; HR, hazard ratio.

^bAdjusted for age, gender, baseline creatinine (<1.0, 1.0 to <2.0, and \geq 2.0 mg/dl), history of hypertension, history of diabetes, history of dyslipidemia, history of CHF, left ventricular ejection fraction, previous MI, use of diuretics, and treatment assignment.

^cFrom the original cohort of 1854 patients, 41 who were not taking captopril at 2 wk as a result of adverse drug reactions (e.g., hypotension, dizziness) were excluded for stratification of risk associated with WRF by treatment.

^dTest for interaction: $P > 0.15$.

^eDeath, MI, CHF hospitalization, and stroke.

remained a significant predictor of WRF in this population of post-MI patients with systolic dysfunction.

Worsening renal function as early as 2 wk after acute MI was associated with a higher incidence of death and was an independent predictor of death (hazard ratio [HR] 1.46; 95% CI 1.05 to 2.02), cardiovascular death (HR 1.62; 95% CI 1.14 to 2.30), and the composite end point (HR 1.32; 95% CI 1.03 to 1.70; Table 2). The prognostic value of WRF not only remained significant after adjustment for covariates but also was a stronger predictor of cardiovascular outcomes than baseline creatinine (HR 1.31 [95% CI 1.01 to 1.70]; HR 1.21 [95% CI 0.91 to 1.61]; HR 1.15 [95% CI 0.95 to 1.39] for death, cardiovascular death, and composite end point, respectively). Although NS, there also was a higher incidence of recurrent MI and hospitalization for CHF in patients with WRF.

A total of 104 (5.7%) patient in the placebo group and 116 (6.4%) patients in the captopril group had WRF, with no difference in the rates of WRF between treatment groups ($P = 0.38$). When stratified by treatment, the risk for death in patients with WRF was higher in the placebo group (HR 1.63; 95% CI 1.05 to 2.52) than in patients who were taking captopril at 2 wk (HR 1.33; 95% CI 0.81 to 2.21). A similar attenuation of risk was observed for the other primary end points as well as hospitalization for CHF (Table 2, Figures 1 and 2). Tests for interaction, however, were NS ($P = 0.49, 0.73, 0.49,$ and 0.37 for death, cardiovascular death, hospitalization for CHF, and the composite end point, respectively).

Discussion

Although baseline renal dysfunction is considered a potent cardiovascular risk factor in post-MI patients, the predictive value of WRF has not yet been addressed in this population. Because ACE inhibition can precipitate acute renal failure in the presence of severe bilateral renal artery stenosis, it is common




Figure 1. Event rate according to worsening renal function (WRF) and treatment group.




Figure 2. Kaplan-Meier curves for death stratified by WRF and treatment group.

practice to withdraw ACE inhibitors when renal function deteriorates; renal artery stenosis is a common finding among patients who undergo coronary angiography (14–18) and among those with heart failure (19). However, this policy may deprive many patients of the potential benefits of these drugs.

In this study of post-MI patients with systolic dysfunction, we observed that WRF, defined as a rise in creatinine of >0.3 mg/dl after 2 wk, was not uncommon (12.0%) and was associated with significantly increased risk for cardiovascular mortality and morbidity. The impact of WRF on outcomes persisted even after adjustment for known covariates and was a stronger predictor of events than baseline creatinine.

The majority of studies that have examined the prognostic value of reduced renal function have focused on serum creatinine values or estimated GFR at one point in time. The predictive value of WRF, however, has been less clear and has been determined primarily in patients who were hospitalized for heart failure, in which the incidence of WRF (27 and 28%) was consistently greater than in SAVE (12.0%) (9,10). More risk factors have proved predictive of WRF in the heart failure population (baseline creatinine, systolic BP, history of diabetes or CHF) than were seen in this population of post-MI patients with systolic dysfunction (age). Few trials have assessed the prognostic value of WRF in the setting of coronary artery disease. Shlipak *et al.* (20) found that WRF, defined as a change of creatinine of >0.3 mg/dl during 4 yr of follow-up, was not associated with outcome in postmenopausal women with stable coronary artery disease in the Heart and Estrogen/Progestin Replacement Study (HERS). No other study has examined the prognostic importance of WRF in the common and important setting of left ventricular dysfunction after MI.

Most clinical studies have defined WRF as an increase in creatinine of >0.3 mg/dl, a threshold that has been found in previous studies to have the highest sensitivity (81%) and specificity (62%) for predicting mortality (13). Initial analyses in our cohort (data not shown) demonstrated a similar threshold effect, with higher event rates occurring in patients with a change in creatinine of >0.3 mg/dl. Lower magnitude changes may be less clinically relevant and represent transient changes or inherent variability in creatinine measurement. However, a more linear or J-shaped association between small changes in creatinine and risk for adverse cardiovascular outcomes also has been suggested (21,22).

The decision to withdraw ACE inhibition in patients who experience elevations in serum creatinine has been controversial (23). Physicians are reluctant to continue treatment with ACE inhibitors when creatinine begins to rise because of concerns about precipitating acute renal failure (24). In proteinuric kidney disease, ACE inhibitors reduce glomerular hyperfiltration by causing efferent glomerular arteriolar vasodilation, and short-term WRF is associated with long-term stability of kidney function (25–28). However, WRF in the setting of coronary artery disease and impaired systolic function probably is more likely to be due to reduced glomerular perfusion rather than glomerular hyperfiltration in the setting of ACE inhibition and therefore may carry a different prognosis. Recent data have demonstrated the benefits of ACE inhibition in patients with advanced renal insufficiency, even when a patient's serum creatinine level continues to increase (29,30). Rapid and more extensive increases would suggest conditions such as bilateral renal artery stenosis or severe hypoperfusion, which warrant discontinuation of ACE inhibition. Butler *et al.* (31) did not find

an association between WRF and ACE inhibitors in heart failure patients. Similarly, we did not observe a greater incidence of WRF in patients who received ACE inhibition in SAVE. Our data may suggest that the relationship between WRF and increased cardiovascular risk could be altered by ACE inhibitor therapy in patients after MI. Although a formal test for interaction was NS, most likely because of inadequate sample size and statistical power given the relatively small number of patients with WRF for each end point, the increased risk associated with WRF seemed consistently lower in the captopril group, raising the possibility that ACE inhibition may alter the relationship between elevation in creatinine and cardiovascular outcomes. This study has allowed for analysis of the effects of ACE inhibition on WRF and cardiovascular risk in a randomized, placebo-controlled setting. These hypothesis-generating results would argue against discontinuation of ACE inhibitor therapy after small increases in creatinine of <0.3 mg/dl.

A number of limitations of this analysis should be noted. Serum creatinine was measured 2 wk after randomization, which occurred on average 11 d after MI. The variation in time may have affected the results through either worsening or improvement of renal function. However, this variation in time not only underscores the prognostic value of WRF but also stresses the importance of repeating serum creatinine measurements from 1 to 3 wk after the acute event. The dosage of study medication (placebo or captopril) also was variable; although the study protocol did not specify that captopril should be stopped in the presence of WRF, titration regimens were left to the discretion of each patient's physician.

Patients who tolerated the initial test dosage were included regardless of whether the study medication was not titrated fully to the target dosage of 25 mg three times daily by the end of 2 wk. The majority of patients were started at 12.5 mg and titrated upward, but there were patients who started at lower dosages or were down-titrated as a result of adverse drug reactions or cardiovascular events before 2 wk, which might have influenced the predictive value of increased creatinine. We would have expected to see an average decline in GFR for patients who started captopril but did not find this in SAVE. This finding most likely was due to variation in dose titration and patients' not receiving the maximum therapeutic effect of captopril. The average change in GFR also may have been influenced by the 41 patients who dropped out of the trial as a result of adverse drug reactions from captopril. Our findings in the placebo group, however, would not have been influenced by dose titration. The results from this *post hoc* analysis were observed in post-MI patients with systolic dysfunction and cannot be extended to those with normal ventricular function. Finally, SAVE was conducted between 1988 and 1991. We cannot exclude the possibility that changes in the treatment of post-MI patients may have altered the current relation between WRF and cardiovascular risk. However, SAVE was conducted in a randomized, placebo-controlled setting and therefore allowed us to assess the true effect of ACE inhibition on cardiovascular outcomes in the setting of renal dysfunction using prospectively collected data.

Conclusion

We have shown that in patients with acute MI and systolic dysfunction, WRF defined as an increase in creatinine of >0.3 mg/dl within the first 2 wk is not uncommon (12.0%) and when present is associated with a significant increase in risk for cardiovascular outcomes and mortality. In this population of patients with systolic dysfunction after MI, WRF was a more robust predictor of events and death than baseline serum creatinine. The risk that is associated with WRF was most prominent in patients who received placebo and seems to be attenuated in patients who receive captopril. These findings suggest that close monitoring of renal function during the first few weeks after acute MI may aid in long-term risk stratification for cardiovascular events and may argue against discontinuation of ACE inhibitor therapy after small, nonprogressive increases in creatinine.

Acknowledgments

The SAVE trial originally was supported by a grant from Bristol Myers Squibb. P.J. was a research fellow supported by the Stanley J. Sarnoff Endowment for Cardiovascular Science, Inc.

References

- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 351: 1296–1305, 2004
- Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. *N Engl J Med* 339: 799–805, 1998
- Chertow GM, Normand SL, Silva LR, McNeil BJ: Survival after acute myocardial infarction in patients with end-stage renal disease: Results from the cooperative cardiovascular project. *Am J Kidney Dis* 35: 1044–1051, 2000
- Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction and renal dysfunction: A high-risk combination. *Ann Intern Med* 137: 563–570, 2002
- Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moye LA, Pfeffer MA, Solomon SD: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) study. *Circulation* 110: 3667–3673, 2004
- Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med* 351: 1285–1295, 2004
- Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. *J Am Coll Cardiol* 35: 681–689, 2000
- Hillege HL, Girbes ARJ, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. *Circulation* 102: 203–210, 2000
- Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RJ: Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. *Am J Cardiol* 85: 1110–1113, 2000
- Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. *J Am Coll Cardiol* 43: 61–67, 2004
- Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM: Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure? *J Card Fail* 9: 13–25, 2003
- Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med* 327: 669–677, 1992
- Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM: The prognostic importance of different definitions of worsening renal function in congestive heart failure. *J Card Fail* 8: 136–141, 2002.
- Harding MB, Smith LR, Himmelstein SI, Harrison K, Phillips HR, Schwab SJ, Hermiller JB, Davidson CJ, Bashore TM: Renal artery stenosis: Prevalence and associated risk factors in patients undergoing routine cardiac catheterization. *J Am Soc Nephrol* 2: 1608–1616, 1992
- Conlon PJ, Little MA, Pieper K, Mark DB: Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. *Kidney Int* 60: 1490–1497, 2001
- Rihal CS, Textor SC, Breen JF, McKusick MA, Grill DE, Hallett JW, Holmes DR Jr: Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. *Mayo Clin Proc* 77: 309–316, 2002
- Khosla S, Kunjummen B, Manda R, Khaleel R, Kular R, Gladson M, Razminia M, Guerrero M, Trivedi A, Vidyarthi V, Elbzour M, Ahmed A: Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography. *Catheter Cardiovasc Interv* 58: 400–403, 2003
- Ix JH, Shlipak MG, Liu HH, Schiller NB, Whooley MA: Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: The Heart and Soul Study. *J Am Soc Nephrol* 14: 3233–3238, 2003
- MacDowall P, Kalra PA, O'Donoghue DJ, Waldek S, Mamtora H, Brown K: Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. *Lancet* 352: 13–16, 1998
- Shlipak MG, Stehman-Breen C, Vittinghoff E, Lin F, Varosy PD, Wenger NK, Furberg CD; Heart and Estrogen/Progestin Replacement Study (HERS) Investigators: Creatinine levels and cardiovascular events in women with heart disease: Do small changes matter? *Am J Kidney Dis* 43: 37–44, 2004

21. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M: Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A prospective cohort study. *J Am Soc Nephrol* 15: 1597–1605, 2004
22. Praught ML, Shlipak MG: Are small changes in serum creatinine an important risk factor? *Curr Opin Nephrol Hypertens* 14: 265–270, 2005
23. Palmer BF: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What to do if the serum creatinine and/or serum potassium concentration rises. *Nephrol Dial Transplant* 18: 1973–1975, 2003
24. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? *Arch Intern Med* 160: 685–693, 2000
25. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D: Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: The CATS randomized trial. *Eur Heart J* 24: 412–420, 2003
26. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. *N Engl J Med* 334: 939–945, 1996
27. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med* 329: 1456–1462, 1993
28. Apperloo AJ, De Zeeuw D, De Jong PE: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. *Kidney Int* 51: 793–797, 1997
29. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. *N Engl J Med* 354: 131–140, 2006
30. Hebert LA: Optimizing ACE-inhibitor therapy for chronic kidney disease. *N Engl J Med* 354: 189–191, 2006
31. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. *Am Heart J* 147: 331–338, 2004